Literature DB >> 33514011

Long Noncoding RNA HOXA11-AS and Transcription Factor HOXB13 Modulate the Expression of Bone Metastasis-Related Genes in Prostate Cancer.

Aya Misawa1, Yukihiro Kondo2, Hiroyuki Takei3, Toshihiro Takizawa1.   

Abstract

Long noncoding RNAs (lncRNAs) are emerging as critical regulators of gene expression, which play fundamental roles in cancer development. In this study, we found that homeobox A11 antisense RNA (HOXA11-AS), a highly expressed lncRNA in cell lines derived from prostate cancer bone metastases, promoted the cell invasion and proliferation of PC3 prostate cancer cells. Transcription factor homeobox B13 (HOXB13) was identified as an upstream regulator of HOXA11-AS.HOXA11-AS regulated bone metastasis-associated C-C motif chemokine ligand 2 (CCL2)/C-C chemokine receptor type 2 (CCR2) signaling in both PC3 prostate cancer cells and SaOS2 osteoblastic cells. The HOXB13/HOXA11-AS axis also regulated integrin subunits (ITGAV and ITGB1) specific to prostate cancer bone metastasis. HOXB13, in combination with HOXA11-AS, directly regulated the integrin-binding sialoprotein (IBSP) promoter. Furthermore, conditioned medium containing HOXA11-AS secreted from PC3 cells could induce the expression of CCL2 and IBSP in SaOS2 osteoblastic cells. These results suggest that prostate cancer HOXA11-AS and HOXB13 promote metastasis by regulation of CCL2/CCR2 cytokine and integrin signaling in autocrine and paracrine manners.

Entities:  

Keywords:  HOXA11-AS; HOXB13; long noncoding RNA; metastasis; prostate cancer

Mesh:

Substances:

Year:  2021        PMID: 33514011      PMCID: PMC7912412          DOI: 10.3390/genes12020182

Source DB:  PubMed          Journal:  Genes (Basel)        ISSN: 2073-4425            Impact factor:   4.096


  64 in total

Review 1.  Homeobox genes and cancer.

Authors:  C Cillo; A Faiella; M Cantile; E Boncinelli
Journal:  Exp Cell Res       Date:  1999-04-10       Impact factor: 3.905

2.  Integrin alpha2beta 1 (α2β1) promotes prostate cancer skeletal metastasis.

Authors:  Joseph L Sottnik; Stephanie Daignault-Newton; Xiaotun Zhang; Colm Morrissey; Maha H Hussain; Evan T Keller; Christopher L Hall
Journal:  Clin Exp Metastasis       Date:  2012-12-15       Impact factor: 5.150

Review 3.  HOX genes and their role in the development of human cancers.

Authors:  Seema Bhatlekar; Jeremy Z Fields; Bruce M Boman
Journal:  J Mol Med (Berl)       Date:  2014-07-05       Impact factor: 4.599

4.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.

Authors:  Xiao-Jun Ma; Zuncai Wang; Paula D Ryan; Steven J Isakoff; Anne Barmettler; Andrew Fuller; Beth Muir; Gayatry Mohapatra; Ranelle Salunga; J Todd Tuggle; Yen Tran; Diem Tran; Ana Tassin; Paul Amon; Wilson Wang; Wei Wang; Edward Enright; Kimberly Stecker; Eden Estepa-Sabal; Barbara Smith; Jerry Younger; Ulysses Balis; James Michaelson; Atul Bhan; Karleen Habin; Thomas M Baer; Joan Brugge; Daniel A Haber; Mark G Erlander; Dennis C Sgroi
Journal:  Cancer Cell       Date:  2004-06       Impact factor: 31.743

5.  Calcification in human osteoblasts cultured in medium conditioned by the prostatic cancer cell line PC-3 and prostatic acid phosphatase.

Authors:  G Kimura; Y Sugisaki; Y Masugi; N Nakazawa
Journal:  Urol Int       Date:  1992       Impact factor: 2.089

6.  HOXB13 promotes ovarian cancer progression.

Authors:  Jiangyong Miao; Zuncai Wang; Heather Provencher; Beth Muir; Sonika Dahiya; Erin Carney; Chee-Onn Leong; Dennis C Sgroi; Sandra Orsulic
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

7.  Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells.

Authors:  Qisheng Tu; Jin Zhang; Amanda Fix; Erika Brewer; Yi-Ping Li; Zhi-Yuan Zhang; Jake Chen
Journal:  J Cell Physiol       Date:  2009-01       Impact factor: 6.384

Review 8.  Integrins as Therapeutic Targets: Successes and Cancers.

Authors:  Sabine Raab-Westphal; John F Marshall; Simon L Goodman
Journal:  Cancers (Basel)       Date:  2017-08-23       Impact factor: 6.639

9.  The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis.

Authors:  Mark M Pomerantz; Fugen Li; David Y Takeda; Romina Lenci; Apurva Chonkar; Matthew Chabot; Paloma Cejas; Francisca Vazquez; Jennifer Cook; Ramesh A Shivdasani; Michaela Bowden; Rosina Lis; William C Hahn; Philip W Kantoff; Myles Brown; Massimo Loda; Henry W Long; Matthew L Freedman
Journal:  Nat Genet       Date:  2015-10-12       Impact factor: 38.330

Review 10.  The complexity of integrins in cancer and new scopes for therapeutic targeting.

Authors:  Hellyeh Hamidi; Mika Pietilä; Johanna Ivaska
Journal:  Br J Cancer       Date:  2016-09-29       Impact factor: 7.640

View more
  5 in total

Review 1.  Newly Released Advances in the Molecular Mechanisms of Osseous Metastasis and Potential Therapeutic Strategies.

Authors:  E Carlos Rodriguez-Merchan; Manuel Peleteiro-Pensado
Journal:  Arch Bone Jt Surg       Date:  2022-09

2.  Long non-coding RNA HOXA11 antisense RNA upregulates spermatogenesis-associated serine-rich 2-like to enhance cisplatin resistance in laryngeal squamous cell carcinoma by suppressing microRNA-518a.

Authors:  Na Shen; Xiaohui Duan; Yong Feng; Jianxin Zhang; Xiaocheng Qiao; Wenyu Ding
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

Review 3.  Downstream of the HOX genes: Explaining conflicting tumour suppressor and oncogenic functions in cancer.

Authors:  Richard Morgan; Keith Hunter; Hardev S Pandha
Journal:  Int J Cancer       Date:  2022-02-15       Impact factor: 7.316

4.  Mutator-Derived lncRNA Landscape: A Novel Insight Into the Genomic Instability of Prostate Cancer.

Authors:  Liansha Tang; Wanjiang Li; Hang Xu; Xiaonan Zheng; Shi Qiu; Wenbo He; Qiang Wei; Jianzhong Ai; Lu Yang; Jiyan Liu
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

5.  Solamargine Inhibits the Development of Hypopharyngeal Squamous Cell Carcinoma by Decreasing LncRNA HOXA11-As Expression.

Authors:  Ying Meng; Mengli Jin; Dai Yuan; Yicheng Zhao; Xiangri Kong; Xuerui Guo; Xingye Wang; Juan Hou; Bingmei Wang; Wu Song; Yong Tang
Journal:  Front Pharmacol       Date:  2022-07-12       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.